Compounds and methods for modulating tissue permeability
AssigneeAdherex Technologies, Inc.
InventorsOrest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
Life of this patent
Estimating the term…
Abstract
Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
Claims31
A cell adhesion modulating agent comprising a cyclic peptide, wherein the cyclic peptide comprises the sequence LYHY (SEQ ID NO:1).
A cell adhesion modulating agent comprising a sequence selected from the group consisting of QYLYHYCVVD (SEQ ID NO:2), YLYHYCVVD (SEQ ID NO:12), LYHYCVVD (SEQ ID NO:13), QYLYHYC (SEQ ID NO:14), YLYHYC (SEQ ID NO:15), LYHYC (SEQ ID NO:16), QYLYHY (SEQ ID NO:17), YLYHY (SEQ ID NO:18) and derivatives of the foregoing sequences having one or more C-terminal, N-terminal and/or side chain modifications.
A cell adhesion modulating agent comprising an antibody or antigen-binding fragment thereof that specifically binds to a cell adhesion recognition sequence bound by an occludin.
A kit for enhancing transdermal drug delivery, comprising:
- (a) a skin patch;
- and
- (b) a cell adhesion modulating agent, wherein said modulating agent comprises the sequence LYHY (SEQ ID NO:1), and wherein said modulating agent inhibits occludin-mediated cell adhesion.
Dependencies are inferred from the claim text.